Efficacy and safety of transdermal buprenorphine patch in cancer patients who are physically dependent on opioids

Gyeongsang National University Changwon Hospital0 个研究点目标入组 53 人开始时间: 待定最近更新: 2020年7月13日

试验速览

暂无简介。

•1. age: 18 years or old
•2. those who have willing to participate in the trial
•3. cancer patients who have been prescribed opioids of MEDD 80 mg or less and who were physically dependent on offending opioids
•4. consistent with DSM-5 diagnostic criteria for opioid withdrawal
•5. those in whom there is no evidence of cancer or cancer have not progressed for more than 6 months
•6. appropriate bone marrow, renal, and hepatic function

•1. co-morbid dependence on high doses of benzodiazepines or other central nervous system depressants or alcohol
•2. hypersensitivity on buprenorphine
•3. those who were treated with MAO inhibitors during the last 2 weeks
•4. pregnant or potential to become pregnant
•5. severe respiratory impairment
•6. significant untreated psychiatric comorbidity including depressive disorders, antisocial and borderline personality disorder
•7. active or chronic suicidal or homicidal ideation or attempts
•8. significant medical complications which are prioritized over participating study
•9. patients who have a significant pain (more than NRS 4) or who are unable to manage cancer pain without opioids
•10. history of being prescribed buprenorphine for any purpose in the last 8 weeks

发起方

Gyeongsang National University Changwon Hospital